Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2982852 | 0.94 | TSHR (0.50) | TSHRSMN1; SMN2HPGDMAPTHTT | |
| SCHEMBL2990248 | 0.93 | TSHR (0.49) | TSHRSMN1; SMN2HPGDMAPTHTT | |
| SCHEMBL2976914 | 0.93 | TSHR (0.49) | TSHRHPGDMAPTHTTGHSR | |
| SCHEMBL2989322 | 0.90 | MEN1 (0.48) | TSHRSMN1; SMN2HPGDMAPTHTT | |
| SCHEMBL2984800 | 0.90 | ALDH1A1 (0.48) | TSHRMAPTGHSR | |
| SCHEMBL2972799 | 0.89 | TSHR (0.52) | TSHRSMN1; SMN2HPGDMAPTHTT | |
| SCHEMBL2987360 | 0.87 | TSHR (0.50) | TSHRSMN1; SMN2HPGDMAPTHTT | |
| SCHEMBL2991421 | 0.87 | OPRM1 (0.47) | TSHRSMN1; SMN2HPGDMAPTHTT | |
| SCHEMBL2976840 | 0.86 | TSHR (0.49) | TSHRSMN1; SMN2HPGDMAPTHTT | |
| SCHEMBL2983538 | 0.86 | TSHR (0.49) | TSHRSMN1; SMN2HPGDMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786328-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2010-08-31 | — | — | US | claimed |
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-12-06 | — | — | US | claimed |
| US-7786328-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2010-08-31 | — | — | US | disclosed |
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | DPYD, PKD1, AOC1 | TSHR 3832/4885SMN1; SMN2 895/4885HPGD 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.